BioMarin Pharmaceutical Inc.
https://www.biomarin.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioMarin Pharmaceutical Inc.
Grünenthal Bolsters US Portfolio With Buyout Of Valinor
Deal snapshot: The German pain-management specialist is acquiring Valinor to gain additional geographic rights to the gastrointestinal drug Movantik and add to its US product portfolio.
Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives
Restructuring Edition: Financial market conditions are improving, but gains have not stopped some companies from cutting costs or shutting down. MEI may wind down if it does not identify another strategic alternative and Aslan has begun to liquidate, while others have cut jobs.
First Four Members Of US FDA’s Newest Advisory Committee Are Mostly Rookies
Most of the new Genetic Metabolic Diseases Advisory Committee members have little FDA or advisory committee experience, except the new industry representative, with six more voting slots still to fill before its first meeting.
Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents
Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- Huxley Pharmaceuticals, Inc.
- LEAD Therapeutics, Inc.
- Prosensa Holding N.V
- Zacharon Pharmaceuticals, Inc.
- ZyStor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice